Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 36

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 36
---
 the end of the listed fiscal year; and (iii) the change      
 in fair value during the listed fiscal year through the vesting date of equity awards granted in prior years that vested during the listed     
 fiscal year, less the fair value at the end of the prior year of awards granted prior to the listed fiscal year that failed to meet applicable 
 vesting conditions during the listed fiscal year. Equity values are calculated in accordance with FASB ASC Topic 718, and the valuation        
 assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant.                             |

| 30 |

| (4) | Measured                                                                                                                             
 as the value of a $100 investment in Imunon common stock at market close on December 31, 2021, the last trading day in 2021, through 
 and including the end of the indicated year.                                                                                         |
| (5) | Calculated                                                                                                                           
 in accordance with U.S. GAAP.                                                                                                        |

Financial Performance Measures

We do not currently use financial performance measures to link executive compensation actually paid to our NEOs to our performance. However, as discussed above under “Executive Compensation,” we do utilize non-financial measures such as clinical development progress and timelines, manufacturing measures and progress towards commercialization.

Analysis of the Information Presented in the Pay Versus Performance Table

As described in more detail above under “Compensation Discussion and Analysis” our executive compensation is designed to (1) attract, motivate and retain talented executives with total compensation that is competitive in our industry; (2) align the interests of our executives and our stockholders; and (3) award behavior which results in optimizing the commercial potential of our development program. We use various performance measures to align executive compensation with our performance which are not presented in the Pay Versus Performance table. In accordance with Item 402(v) of Regulation S-K, we are providing the following description of the relationships between the information presented in the Pay Versus Performance table.

Table Compensation Actually Paid and Cumulative TSR

The amount of compensation actually paid to Dr. Lindborg, Mr. Tardugno and Dr. Le Goff in 2024, Dr. Le Goff in 2023, and Mr. Tardugno and Dr. Le Goff in 2022 is aligned with our TSR over the two years presented in the table, reflecting the impact of (i) the hiring of Dr. Lindborg as President and Chief Executive Officer in 2024 and the